Abstract: Analysis of genetic changes is often hampered by insufficient starting DNA from limited clinical tissue specimens. We employed ligation-mediated PCR (LM-PCR) for global amplification of the genome to overcome this limitation, generating up to 5 µg of representative amplicons of genomic DNA from as little as one cell. We demonstrate successful global genome amplification in high-quality starting DNA source like laser-captured cultured cells, as well as partially degraded starting DNA from old formalin-fixed paraffinembedded tissue sections. This process generates adaptor-tailed templates that can be repeatedly amplified almost ad infinitum. We have further modified this technique such that, instead of a single endonuclease digest, we can achieve higher amplicon coverage by combining 3 endonuclease digests prior to LM-PCR. As tested by examining amplification of STS sequences scattered genome-wide, the coverage was improved from the published 70% to 96%. The faithful representation of global losses and gains in the amplified genomic DNA was confirmed by array-comparative genomic hybridization. Further, we exemplify the utility of this technique for finer p53 point mutation analysis by PCR-SSCP. This technique is thus a clinically useful tool for globally amplifying and archiving DNA from finite sources like paraffin tissue sections, providing a potentially unlimited resource for genetic analyses.
G enetic alterations play an important role in the development of tumors. 1 A variety of molecular analyses, including southern hybridization, loss of heterozygosity (LOH) analysis, and comparative genomic hybridization (CGH), have permitted determination of genetic alterations during tumor progression. [2] [3] [4] Although formalin-fixed paraffin-embedded (FFPE) tissues are the most abundant tissue source for both investigative and clinical studies, particularly for retrospective studies with tissues that have associated clinical outcome data, these are far from an ideal source for genetic analysis for clinical research. 5, 6 The primary reason for this is that the quality and quantity of DNA extracted from FFPE tissue sections varies significantly with the differences in fixation methods and storage time, and high-quality DNA can often be obtained in only severely limited quantities from many of these tissues. Therefore, application of many genetic analyses in FFPE tumor tissue sections is often unsuccessful.
Another problem in tumor genetic analysis is the existence of heterogeneous populations of cells within tissues. One way to selectively isolate target cells from such heterogenous population is laser-captured microdissection (LCM). 7 However, LCM samples are typically extremely small, often even single cells. Therefore, DNA acquired from LCM samples is frequently insufficient for single and/or multiple genetic analyses.
To overcome the limitation of material availability described earlier and improve upon the utility of these precious resources, a technique for global genome amplification is necessary, such that the amplification products closely resemble the original template DNA (i.e., they are highly 'representative'). Lucito et al have described such a general method for amplifying genomic DNA in a representative manner. 8 They employed the preparatory step of representational difference analysis technique to generate representative amplicons (RA), which are a set of endonuclease cleavage fragments amplified by ligation-mediated PCR (LM-PCR). One limitation of this method is that the RA cannot be wholly representative of the genomic sequences, since some of these sequences fail to amplify during the procedure, either due to the large amplicon size or the presence of restriction endonuclease cleavage site within the target region. Thus, although the technique was shown to work with genomic DNA from cultured cells (which, incidentally, is the most optimal study material), it could amplify DNA in a representative manner with only limited ge-nome coverage by the RA. Nevertheless, this study laid the ground-work for a way to create essentially renewable genomic DNA libraries from finite starting amount.
The goals of our present study were (1) to examine the ability of this technique to amplify DNA extracted from archival FFPE tissue and LCM-derived cells, (2) to extend the application of this technique to standard genetic analyses, and (3) to enhance the LM-PCR technique so as to allow for more highly representative amplification for the entire genome. We demonstrate that the genomic DNA from not only cultured cells but also archival FFPE tissue sections and LCM-derived cells from cultured cell preparations, spread and fixed on a slide, can be successfully used as a template for LM-PCR. Using DNA from cultured cells and archival FFPE tissue sections as the test models, the coverage of RA can be significantly enhanced by combining 3 endonuclease digests before LM-PCR. It should be noted that LCM-derived cells were not included in this experiment. In addition to using RA as a template to perform STS sequence-specific PCR, we show that the RA can also be used to determine gene losses and gains at a global level by array-comparative genome hybridization (CGH), as well as for detection of specific p53 point mutation in cancer cells by PCR-SSCP. This demonstrates fidelity and capability of this technique in genetic analyses at a variety of genomic levels.
MATERIALS AND METHODS

Human Cell Lines and Formalin-Fixed Paraffin-Embedded Tissues
One human prostate cancer cell line (LNCaP), 3 bladder cancer cell lines (T24, RT4, 5637), and 8 FFPE cancer tissues (arbitrarily designated as PS-1 to PS-8) were included in this study. While 6 of the latter (PS-1∼PS-6) were tested for STS coverage, 4 tissues (PS-1, PS-2, PS-7, and PS-8) were used for gene mutation detection. The cell lines used were all procured from American Type Cell Culture. The FFPE tissue blocks used were excess surgical pathology specimens processed routinely, which were procured after stripping them of all patientidentifiers. The inclusion of these tumor tissue blocks in the study was approved by the USC institutional review board. All FFPE tissue sections represented invasive cancer with dense cellularity. Among them, 2 were prostate cancers (PS-3, PS-4), while the others were bladder cancers (PS-1, PS-2, PS-5, PS-6, PS-7, and PS-8). Prior to use, these tissue blocks had been stored under standard conditions for periods ranging from 2 years to 25 years.
Isolation of Genomic DNA From Cultured Cells and FFPE Tissue Sections
For cultured cells, genomic DNA was extracted following a method by Blin and Stafford. 9 For FFPE tissues, one 20-µ thick tissue section from each tissue block was used to macrodissect the tumor portion away from adjacent normal tissue under microscope using H&E-stained slides as template. Macrodissected tumor cells were collected into a microcentrifuge tube and deparaffinized by incubating in 1mL xylene for 3 hours, with 2 hourly changes. This was followed by rehydration in 100% and 75% ethanol for 30 minutes each. Cells from the sections were lysed by an overnight incubation at 55°C in lysis buffer (10 mmol/L Tris-HCl, 1mmol/L EDTA, 1 mg/mL proteinase K, 1% Tween-20). DNA was isolated following standard phenol-chloroform extraction and isopropanol precipitation. 9 Two µg of the isolated genomic DNA was electrophoresed in 1.5% agarose gel to assess the quality.
Isolation of Genomic DNA From LCM Cells
Cultured LNCaP cells were centrifuged on glass slides (Hettich Zentrifugen, Tuttlingen, Germany, model Universal 16A), air dried overnight, and fixed in acetone. The PixCell LCM system (Arcturus, Mountain View, CA) was used to microdissect centrifuged LNCaP cells. Different quantities of cells (1, 5, 10, 20 , and 50) were captured onto separate CapSure LCM caps. Genomic DNA was extracted using PicoPure DNA Extraction kit (Arcturus, Mountain View, CA, Cat. #KIT0103) according to manufacturer's instructions. Briefly, following laser capture, CapSure LCM Cap was inserted into the microcentrifuge tube with 50 µL proteinase K extraction solution provided in the kit, and microcentrifuge tube was inverted to ensure that extraction buffer covered the CapSure LCM Cap. After incubation at 42°C for 3 hours, the lysate was centrifuged at 1000g for 1 minute and the proteinase K was inactivated by heating at 95°C for 5 minutes. The isolated DNA was further used for endonuclease digestion.
Generation of Representative Amplicons by Single Endonuclease Digest
Generation of representative amplicons (RAs) consisted of 4 main steps: restriction cleavage, adaptor ligation, first PCR, and second PCR. Genomic DNA, 10 ng, was digested separately with either DpnII, HhaI, or RsaI (New England Biolabs, Beverly, MA, Cat. # R0543S, R0139S, R0167S, respectively) under conditions suggested by the supplier. Each digest was purified using MiniElute Reaction Cleanup kit (Qiagen, Valencia, CA, Cat. # 28104) and was resuspended by addition of 0.45 nmol of adaptors (A1 and A2 for DpnII digests, A1 and A3 for HhaI digests, A1 and A4 for RsaI digests, see Table 1 for adaptor sequences), 2 µL T4 DNA ligase buffer (New England Biolab, Beverly, MA), and deionized water in a total volume to 20 µL. All adaptor sequences were synthesized at USCNorris Comprehensive Cancer Center Microchemical Core Facility. The adaptor annealing reaction tube was placed in a 55°C heating block for 10 minutes and allowed to cool for about 45 minutes to approximately 16°C by placing the heat block in refrigerator. Four hundred units of T4 DNA ligase (New England Biolab, Beverly, MA, Cat. #M0202S) were then added, and the ligation reaction tube was further incu-bated at 16°C overnight. The following reagents were added to the ligated material: 40 µL of 5×PCR buffer (335 mmol/L Tris·HCl, pH 8.8, 20 mmol/L MgCl 2 , 80 mM (NH 4 ) 2 SO 4 , 50 mmol/L mercaptoethanol, 0.5 mg/mL of BSA), 64 nmol dNTPs, 0.12 nmol adaptor A1 (which served as primer), and deionized water to bring the volume to 200 µL. In each case, the tube was placed in a thermal cycler preheated to 72°C, and 15 units of Taq polymerase (Invitrogen, Carlsbad, CA, Cat. #10966026) was added to every tube. The 3Ј-end filling reaction for the ligated molecules was continued at 72°C for 5 minutes, followed by 20 amplification cycles (first PCR), each comprising of 1-minute denaturation at 95°C and 3 minutes chain extension at 72°C, with final extension of 10 minutes at 72°C following the last cycle. Since the primers and dNTPs might be exhausted in the first PCR, second PCR was carried out to refresh the reaction. Meanwhile, the remaining first PCR product was saved as the resource for further amplification. For second PCR, one fourth of the first PCR product volume and the following reagents were added into each tube: 30 µL 5×PCR buffer (composition as described earlier), 64 nmol dNTPs, 0.12 nmol adaptor A1, and water to bring the volume to 200 µL. The amplification was carried out for an additional 15 cycles with the same thermal profile as described above, with a final extension at 72°C for 10 minutes. The products were purified by QIAquick PCR purification kit (Qiagen, Valencia, CA, Cat. #28104). The quantity of purified RAs of genomic DNA was determined by spectrophotometry. PCR reaction mixture with deionized water added instead of the template DNA was used as negative control. The genomic RAs were electrophoresed in 2% agarose gel in TBE buffer.
Generation of Combinatorial RAs Using 3 Endonucleases
This modification was attempted to improve the genomic coverage of the RA, and the following strategy was used to increase the global coverage of RA. Genomic DNA was equally divided and separately digested with 3 restriction endonucleases with different cutting frequency and sequence specificity (DpnII, HhaI, and RsaI). The digests were then combined to prepare the combinatorial RAs. Simultaneously, RA was also generated using individual endonuclease digests to compare and determine the differences in both regional coverage and global coverage. Genomic DNA from cultured LNCaP cells and 2 FFPE tissue sections (PS-1, PS-2) were used for testing the enhancement of coverage as a proof of principle. Ten ng genomic DNA was equally divided into 3 tubes and separately digested by DpnII, HhaI, and RsaI. The 3 digests were then combined and adaptors (A1, A2, A3, and A4) were added to complete annealing of ligation reactions. RA was then generated as described earlier.
PCR for Sequence-Tagged Sites Using RA as Templates
To assess the extent of genomic capture by the RA, a series of sequence-tagged sites (STSs) sequences were amplified by PCR using RA as templates. The choice of target STS sequences was based on the following 2 considerations: (1) that the target STS sequences are distributed genome wide and (2) that the target STS sequences are located in or around the genes crucial in cancer initiation and progression. The target STS sequences used are listed in Table 2 . The primer-pair sequences and PCR thermal profile for each STS sequence were derived from National Center for Biotechnology Information (NCBI) web site (http://www.ncbi.gov/Entrez/). 
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Twenty-three STSs proximal to or within known cancerassociated genes on 20 human chromosomes, with size range between 100 bp to 500 bp, were chosen as PCR targets to test the coverage of RA. Successful LM-PCR amplification of an STS implied that the target sequence could be captured by the RA, while a failed STS amplification denoted loss of the target sequence during the preparative procedure. The amplifiability of target sequences by LM-PCR is thus limited by the distribution of restriction endonuclease cleavage sites. For example, due to the presence of DpnII cleavage sites within 11 of the target STS sequences, only 12 of the 23 STS sequences studied here are theoretically amplifiable following DpnII digestion ( Table 2) .
For RA generated from LNCaP, PS-1, and PS-2, all STS sequences were used to test the coverage, while for RA generated from PS-3 to PS-6, only the STS sequences without DpnII internal cleavage sites were used to test the coverage.
Genetic Analysis by Array-CGH Using RA
RA was generated from genomic DNA of 2 bladder cancer cell lines (TCC, RT4) (test DNA) as well as genomic DNA from normal human lymphocytes (reference amplicon) (Promega, Madision, WI) using DpnII digest alone. Array-based comparative genomic hybridization (CGH) was performed on bladder cancer cell lines employing previously described protocols. 10, 11 The FFPE tissue sections and LCM-derived cells were excluded from this analysis, and array-CGH was not performed on RA produced by digest combination. Briefly, the CGH arrays containing 2400 BACs spanning the human genome at approximately 1MB resolution were used as "probe."
12 DNA, 100 ng, was labeled by random primed extension; test DNA was labeled with Cy3 dUTP and reference DNA with Cy5 dUTP. Globally amplified test DNA (TCC-RA or RT4-RA) was hybridized against globally amplified reference DNA (ref-RA), while unamplified test DNA against unamplified reference DNA. Log2 intensity ratios were obtained as a measure of genomic copy number for each sample and these were plotted against genomic distance.
Detection of Point Mutation in p53 Gene Using RA
The analyses for point mutations in p53 gene were performed on 3 bladder cancer cell lines (RT4, T24, and 5637) and 4 FFPE tissue sections (PS-1, PS-2, PS-7, and PS-8). The PCR for p53 gene region spanning exons 5-8 was performed using RA as templates, and the presence of p53 point mutations was determined by SSCP analysis and sequencing, as described in Esrig et al. 13 Briefly, aliquot of the PCR reactions was electrophoresed in 6% nondenaturing polyacrylamide gel containing 10% glycerol, overnight at room temperature using TBE gel buffer. Silver Staining Plus kit (Bio-Rad, Hercules, CA, Cat. #161-0449) was used to identify band shift due to SSCP. The PCR-SSCP results were confirmed by custom automated DNA sequencing (Laragen Inc., Los Angeles, CA).
RESULTS
Global Amplification of Genomic DNA From Cultured Cells Using DpnII Alone
Starting from 10 ng genomic DNA, amplification to approximately 144 µg of RAs could be achieved after 35 cycles. Electrophoresis in 2% agarose gel showed that the size distribution of RA spanned from 200bp to 2kb (Fig. 1) .
Twenty-three STSs were chosen as PCR targets to test the coverage of RA. However, the amplifiability of target sequences by LM-PCR is limited by the distribution of restriction endonuclease cleavage sites. In this context, we have designated 2 terms: "regional coverage" (x/y) and "global coverage"(x/z), where x is the number of target STS sequences actually amplified, y is the number of target STS sequences that do not contain a cleavage site and hence are amplifiable following digestion with a given endonuclease, and z is the total number of STS sequences that are tested. Thus, for a Dpn II digest, where the panel of 23 STS studied here is tested, x/12 would be regional coverage while x/23 would be global cov- erage. Since the ability of an RA preparation to successfully amplify target sequences in a manner highly representative of the template genomic DNA is dependent on the faithful capture of template sequences in successive amplification steps, it is desirable to achieve global coverage approaching 100%.
When the RA prepared from LNCaP DNA using DpnII digestion were tested for coverage, all the 12 STS lacking a DpnII cleavage site could be amplified successfully, indicating 100% regional coverage (12/12 STS), while the same RA showed only 52% global coverage (12/23 STS). We tested the specificity of RA generation by attempting amplification of 4 STS sequences that do contain an internal DpnII cleavage site (and hence should not be amplified).
Using completely digested RA as a template, this contention was confirmed for all the 4 STS amplicons tested. Representative results for 2 of these STS (namely, G13475 and G13540) are shown in Figure 2 . While the undigested genomic DNA showed the PCR product, STS amplification was not seen, as predicted, in the DpnII digestion products.
Enhancement of the Global Coverage of RA by Combing Endonuclease Digests
LNCaP genomic DNA was equally divided and separately digested with 3 restriction endonucleases (DpnII, HhaI, and Rsal), and the digests were then combined to prepare the combinatorial RA. Meanwhile, RA was also generated using individual endonuclease digests to compare and determine the differences in both regional coverage and global coverage.
For LNCaP RA generated from RsaI alone, only 9 out of 23 STS could be used to test the coverage owing to presence of RsaI cleavage site within the rest. The regional coverage was demonstrated to be 100% (9/9), and the global coverage was 39% (9/23). Similarly, for LNCaP RA generated from HhaI digestion alone, 21 of the 23 STS sequences could be used to test the coverage. While the regional coverage was demonstrated to be 81% (17/21), with the global coverage was 74% (17/23). As stated earlier, for LNCaP RA generated from DpnII alone, regional coverage was 100% (12/12), with the global coverage being 52% (12/23) . While use of single endonuclease digest produces only limited global coverage in this study, it was found that 22 of 23 STS could be reproducibly amplified from the RA when the combinatorial digests for three endonucleases (DpnII, HhaI and RsaI) were used, resulting in 96% global coverage. Thus, the target STS sequences that could not be amplified using one endonuclease digest were amplifiable from the digest using other endonuclease(s), thus complementing RA generation to yield significantly enhanced the global coverage (Fig. 3) . The results are summarized in Table 3 .
Global Amplification of Genomic DNA From FFPE Tissue Sections Using DpnII Alone
Six identity-delinked tumor blocks (stored for periods ranging from 2 to 25 years) were used for DNA isolation from their paraffin-embedded tissue sections (designated PS-1 to PS-6). As expected, the DNA samples were partially degraded (Fig. 1) . One hundred to 120 µg RA could be obtained from a starting amount of 10 ng genomic DNA following 35 cycles of PCR. These data indicate that the RA could be reproducibly generated regardless of the length of storage of tissue source and the extent of degradation of the starting genomic DNA. When tested for single endonuclease digests, the regional coverage varied from 67% to 100% (8/12 to 12/12 target STS sequences amplified), with low global coverage ranging from 35-52% (8/23 to 12/23 target STS sequences amplified) ( Table  4 , Fig. 4) .
Enhancement of the Global Coverage of RA Generated From FFPE Tissue Sections by Combing Endonuclease Digests
DNA from 2 paraffin-embedded bladder cancer tissue sections (PS-1 and PS-2) was used to test for enhancement of global coverage using combination of endonuclase digests as a starting point for LM-PCR. For PS-1 and PS-2 RA generated from RsaI digests alone, the regional coverage was 79% (7/9) and 100% (9/9) respectively, and the corresponding global coverage was 30% (7/23) and 39% (9/23). When RA was generated using HhaI digests alone, the regional coverage was 43% (9/21) for both and the corresponding global coverage was 39% (9/23) for both. In comparison, the global coverage for RA generated from the combined digests with 3 endonucleases (DpnII, HhaI, and RsaI) was dramatically enhanced to 96% (22/23). The results summarized in Table 4 demonstrate that RAs can be obtained even from suboptimal starting materials using our enhancement strategy.
Global Amplification of Genomic DNA From LCM-Derived Cells Using DpnII Alone
Cytocentrifuged LNCaP cells were subjected to LCM, separately collecting 50, 20, 10, 5, and 1 cells. LM-PCR was FIGURE 2. The failure for amplification of STS sequences to generate representative amplicons by PCR when the target sequences contain internal cleavage site(s). STS G13475 and G13540 contain the internal cleavage sites for DpnII. When the RA generated from DpnII was used as template for PCR for these two STS, no PCR product was obtained (lanes 1 and 3 used DpnII RA as template). Lane 2 and 4 were positive control for STS (LNCaP genomic DNA).
Diagn Mol Pathol • Volume 13, Number 2, June 2004
LM-PCR and Whole Genome Amplification employed to globally amplify the genomic DNA following endonuclease digestion with DpnII. Five micrograms of RA could be obtained after 35 cycles of LM-PCR starting from genomic DNA obtained from a single cell. The yield increased (albeit in a nonlinear manner) with the higher numbers of LCM-derived cells, and as much as 35.6 µg of RA could be generated from 50 LCM-derived cells (Table 5) . PCR with primers for 12 STS sequences was used to test the coverage of the RA generated from these LCM cells. Starting with 50 LCM-derived cells, the coverage of up to 91.7% could be achieved. The coverage, however, was lower (58.3%) when genomic DNA from a single cell was used as a starting material. The yield and coverage of RA generated from LCMderived cells are summarized in Table 5 .
Genetic Analysis by Array-CGH Using RA
DNA following global amplification was found to be of sufficient quality and quantity to be hybridized by array CGH.
Though the globally amplified DNA (RA) displayed greater variability of copy number ratios (i.e., the ratios from replicate BAC spots showed a higher standard deviation), the RAs exhibited the same genetic aberrations as in the fresh DNA for most regions of the genome. In other words, majority of the alterations (75%∼80% of gene losses and 50%∼60% of gene gains) seen in unamplified DNA were seen to be faithfully represented in the globally amplified RA. In TCC cells, RA showed 10 of 15 changes seen in the unamplified DNA, and in RT4 cells, 13 out of 17 chromosomal alterations were detectable. For example, unamplified DNA of TCC cells exhibited gene losses at chromosome 2, 4, 6p, 6q, 13, 17p, 18q, and X, while the globally amplified RA exhibited the same genetic alterations at chromosome 2, 4, 6q, 13, 18, and X. The comparison of profiles of genetic change between globally amplified DNA (RA) and unamplified DNA is summarized in Table  6 . Figure 5 shows a few chromosomal examples of the arraybased profiles obtained with RA and unamplified DNA. The complementary effect of coverage by combining three endonuclease digests to generate RA. The STS that were unamplifiable by RA generated from any of the restriction endonucleases due to the presence of internal cleavage sites could be amplified by RA generated from combining digests of the three endonucleases. Thus, for example, STS G14707 has cleavage sites for DpnII and RsaI but not for HhaI, hence on combining the digests to generate RA, the combinatorial RA could be used as template to amplify this sequence. Using this strategy, all the STS shown here could be amplified by combinatorial RA. M, 100bp marker; D, RA generated from DpnII digests; H, RA generated from HhaI digests; R, RA generated from RsaI digests; C, RA generated from combination of 3 digests; +, positive control (LNCaP genomic DNA); ‫,מ‬ negative control (without template).
Detection of p53 Gene Mutation Using RA
Three human bladder cancer cell lines (RT4, T24, and 5637) with known p53 gene status were used to determine the utility of RA for the detection of point mutations. While RT4 and T24 are known to be wild type for p53 exons 5-8, cell line 5637 harbors a point mutation at exon 8 (G→C transversion at codon 280). When PCR-SSCP assay was performed using RA generated from these cell lines, the p53 point mutation at exon 8 could be correctly identified for 5637 cell line, consistent with the previously published results, 14 and no mutation was evident for the RAs derived from genomic DNA of the other 2 cell lines (Fig. 6) .
Subsequently, the PCR-SSCP assay was also performed on RA generated from genomic DNA extracted from FFPE tissue sections derived from four human bladder cancers (PS-
1, PS-2, PS-7, PS-8)
. PCR-SSCP analysis demonstrated a p53 point mutation for PS-7 at exon 7 (Fig. 7) . Custom automated DNA sequencing (data not shown) confirmed that PS-7 indeed showed a point mutation (A→G) at codon 258 (exon7).
DISCUSSION
Neoplastic cells analyzed for genetic alterations usually constitute only a small fraction of the cells in the specimen. Even after successful isolation of DNA, limited yield permits only a few genetic analyses. Therefore, availability of a reliable and reproducible method for global genomic DNA amplification is a prerequisite for molecular analyses for a smallsized clinical sample. Successful global amplification of genome should meet 2 desirable requirements. The first requirement is to increase the total amount of amplifiable tem- LNCaP, representative amplicons generated from genomic DNA of human prostate cancer cell line LNCaP; PS-1, PS-2, representative amplicons generated from genomic DNA extracted from formalin-fixed paraffin-embedded tissue sections. *For the PCR using representative amplicons generated from LNCaP genomic DNA as templates, LNCaP genomic DNA was used as positive control. †For the PCR using representative amplicons generated from paraffin-embedded tissue sections, the genomic DNA extracted from the corresponding paraffin sections was used as positive control.
plate DNA (yield) significantly. The second is to ensure that the process of amplification is least biased for certain sequences and that as many sequences in the starting genomic DNA as possible are amplified (indicative of wide coverage and high overall representativeness). The ligation-mediated PCR technique presented here for global genome amplification was evaluated by these 2 criteria.
We have shown here that substantial yield of globally amplified genomic DNA can be achieved, with as much as 150 µg of representative genomic amplicons derived from nanogram amounts of starting genomic DNA. In fact, 5 µg of RA could be obtained from DNA derived from one single cell. Since the RA can be readily reamplified by virtue of the ligated adaptors that serve as primer binding sites, these amplicons become a practically unending, renewable resource for genomic DNA from finite archival cellular material. Importantly, regardless of the periods of storage for tissue blocks, the RA could be generated to serve as template for successful amplification of different target STS sequences ranging in size from 100 to 500 bp, chosen to span the genome globally.
The simple modification in the LM-PCR technique we have designed here, that is, combining digests from several endonucleases prior to LM-PCR, considerably increased the coverage to 96%, producing amplified DNA with representation higher than that previously described (70%). 8 Furthermore, we have shown the use of DNA from archival tumor tissue sections and LCM-derived cells to achieve both high yields and reasonable coverage. Since the LCM-derived cells were obtained from cultured cells spread on a glass slide under ideal conditions, the results may differ for DNA obtained from the LCM cells from human cytologic preparations. The significance of this technique lies in the fact that it successfully addresses 2 main problems in dealing with specimens concerning DNA analysis: insufficient amount and poor quality of extracted DNA. Since some genomic sequences often fail to be amplified during the previously described procedure of whole genome amplification, 8 limited genomic coverage of the amplified products becomes one of the major issues for genetic analysis. Thus, in the original report describing application of LM-PCR for whole genome amplification, only 14 out of 22 (63.6%) STS could be successfully amplified using RA as template, suggesting less than 70% regional coverage. We demonstrate in the present study that the regional coverage can easily be regulated by the choice of restriction endonucleases used for DNA digestion. PCR does not amplify all genomic fragments with equal efficiency, with poorer amplification of the larger fragments. Hence, an endonuclease that cleaves infrequently (rare-cutter) will give rise to longer fragments after endonuclease digestion, yielding lower regional coverage. Our results Note. Regional coverage, the coverage of RA was calculated based on the number of STS which was testable by PCR. For RA generated from DpnII, 12 STS were tested. For RA generated from HhaI, 21 STS were tested. For RA generated from RsaI, 9 STS were tested. Global coverage, the coverage of RA was calculated based on the number of all STS included in this study, which was 23.
LNCaP, RA generated from genomic DNA of human prostate cancer cell line LNCaP; PS-1-PS-6, RA generated from genomic DNA extracted from formalinfixed paraffin-embedded tissue sections. The storage time for PS-1 to PS-6 was 2, 2, 4, 20, 20, and 25 years, respectively. *For the PCR using RA generated from LNCaP genomic DNA as templates, LNCaP genomic DNA was used as positive control. †For the PCR using RA generated from paraffin-embedded tissue sections, the genomic DNA extracted from the corresponding paraffin sections was used as positive control. confirm this concept. Among the 3 endonucleases with different cutting frequency (RsaI > DpnII > HhaI), HhaI results in the lowest regional coverage (43%-81%) compared with other 2 endonucleases, DpnII and RsaI (78%-100%). Although a frequent-cutter would allow higher regional coverage, the global coverage will suffer because of the more numerous cleavage sites in genomic DNA. The unsatisfactory global coverage for RA generated from individual digests with the 3 endonucleases ranged from 30% to 81% depending on the cutting frequency of the endonuclease.
Obviously, the choice of restriction endonuclease is not limited to the 3 attempted here. For the DNA analysis for known sequences, the selection of endonuclease used for LM-PCR could depend on (1) the subsequent genetic analysis and (2) the need to avoid cleavage within the target sequences.
While we may avoid using an endonuclease when targeting a specific known gene sequence, careful selection of endonuclease(s) is necessary to amplify and capture as much of the whole genome sequence as possible when the target sequences for further analysis are unknown. We have introduced here a straightforward strategy to increase the global coverage of RA by combining 3 endonuclease digests (2 frequent cutters, RsaI and DpnII, and 1 rare cutter, HhaI). As shown in this study using the cultured LNCaP cells and 2 FFPE tissue sections, some genomic sequences unamplifiable from the RA generated from digest with a single endonuclease can easily be amplified by the combinational RA because of the absence of internal cleavage site(s) for at least 1 endonuclease used. The combination of the digests from the 3 endonucleases results in complementary, overlapping and/or redundant RA, achieving the maximum global coverage. We have shown remarkable enhancement of the global coverage to as high as 96%. The enhancement of global coverage could be partially attributable to the mechanism of "jumping PCR." 15 The strategy of combinatorial digests was not tested on RA generated from LCMderived cells. Importance of the combination of endonuclease digests thus lies in 2 aspects: (1) the achievement of both high yield of RA and high coverage by the RA and (2) the ability to study unknown gene sequences, such as in endeavors for gene discovery.
Currently, degenerate oligonucleotide-primed-PCR (DOP-PCR) and primer extension preamplification are the 2 FIGURE 4. The amplification of STS sequences by PCR using RA generated from FFPE tissue sections after DpnII digestion alone. Most STS sequences (e.g. G0666) can be successfully amplified by using RA as template, while a few STS sequences (such as G24410) failed to be amplified in some RA (PS-3) (Panel A), which suggests that these sequences were either not captured during genomic DNA amplification procedure or lost by the cancer cells during carcinogenesis. The starting materials for RA generation (genomic DNA before LM-PCR) were used as positive control for STS PCR (Panel B). commonly used methods to perform whole genome amplification; both these methods use degenerate or partially degenerate primers. [16] [17] [18] [19] [20] [21] [22] However, the coverage of DNA amplicons is unknown. Recently, Stoecklein et al compared the effectiveness of two whole genome amplification approaches; DOP-PCR and LM-PCR based SCOMP (single cell comparative genome hybridization). 23 While for DOP-PCR 5000 cells were needed to achieve a yield allowing hybridization that met the standard requirements for CGH, SCOMP amplification produced much clearer CGH profiles with as few as 20 nuclei from archival tissues. These findings suggest that LM-PCR may be superior to DOP-PCR for global genome amplification. 24 We demonstrate here the suitability of RAs obtained from LM-PCR in genetic analysis from broader genomic level (analyzable by techniques such as array CGH) to regionally confined level (analyzable by techniques like STS-PCR) to, finally, finer nucleotide level (such as point mutation detection in a gene by PCR-SSCP). Such genetic analysis can be achieved in cell lines, LCM-derived cells as well as paraffinembedded tissue sections. Application of LM-PCR-mediated RA generation for other genetic studies such as Southern blotting, LOH analysis, and comparative genomic hybridization has been shown elsewhere. 8 Application of a similar LM-PCR-mediated whole genome amplification protocol to rare cells in clinical samples has also been demonstrated. 23 A few aspects require further improvement and study. For example, there may be a need to demonstrate the value of LM-PCR for the LCM cells from FFPE tissue sections that were not evaluated in this study. Similarly, the usefulness for array-CGH performed on RA from FFPE tissue sections and LCM-cells from FIGURE 5. Array-CGH analysis using RA. Example of arraybased CGH chromosomal genomic profiles comparing fresh DNA to RA DNA for the RT4 and TCC cell lines. Each plot represents copy number changes along a chromosome. The values plotted are the log2 ratios of test over reference samples for each BAC clone. Normal copy number is set to zero and values which are greater than a log2 ratio of 0.2 are considered increased in copy number for that region, and if below ‫,2.0מ‬ these are considered as losses. Figure 7A shows an amplicon on chromosomal arm 6p which is found in both RA (lighter squares) and fresh (dark triangles) TCC cell line DNA. Figure 7B shows a small region of loss on chromosomal arm 18q for 2 BACS, indicative of a homozygous deletion, and is present in both RA (lighter squares) and fresh (dark triangles) RT4 cell line DNA. FFPE tissue sections also needs to be pursued further. Another potential study would be to evaluate the possible application of RA for whole genome mutation scanning since, in the present study, the detection of gene point mutation was shown to be successful only in smaller fragment of DNA (<500bp).
In conclusion, it is evident that DNA obtained from very small-sized precious biologic samples can be globally amplified using the LM-PCR technique described here and can allow nearly infinite number of subsequent molecular genetic analyses. This is highly significant for the studies dealing with cells in small numbers, such as occult metastatic cancer cells in bone marrow and lymph nodes, 25 stem cells, or early embryonic cells. Finally, this technique should directly allow for the formation of DNA banks from limited tissue sources such as archival FFPE tissue sections and may allow us to study genetic events in rare cell populations like metastatic cells in peripheral blood, lymph nodes, or bone marrow. FIGURE 7. PCR-SSCP analysis for p53 point mutations in bladder cancers. The formalin-fixed paraffin-embedded tissue sections from 4 bladder cancer patients (designated PS-7, PS-8, PS-1, PS-2) were analyzed for p53 exon 7 mutation by using either the representative amplicons (A) or unamplified genomic DNA (B), positive control). Lanes 1 and 5 represent PS-7; Lanes 2 and 6 represent PS-8; lanes 3 and 7 represent PS-1; lanes 4 and 8 represent PS-2. The arrowhead points to a mobility shift indicating the mutation in PS-8 (lanes 2 and 6). The p53 gene mutation in exon 7 detected by PCR-SSCP shown here is confirmed by DNA sequencing (data not shown).
